Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabeth Cohen

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Neuro-Oncology Advances|May 30, 2024
TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive gliomaAlberto Picca, Anna Luisa Di Stefano, Julien Savatovsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2025
Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I StudyDinu Stefan, Paul Lesueur, Justine Lequesne, et al.
Cancers|November 26, 2022
Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade <i>IDH</i>-Mutant Gliomas: A French POLA Network StudyColine Montégut, Jean-Sébastien Guillamo, François Ducray, et al.
Neuro-Oncology|August 11, 2022
Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network studyAntoine Seyve, Caroline Dehais, Olivier Chinot, et al.
Trends in Cancer|March 30, 2023
Challenges in glioblastoma research: focus on the tumor microenvironment: (Trends in Cancer, 9:1 p:9-27, 2023)Andreas Bikfalvi, Cristine Alves da Costa, Tony Avril, et al.
Neurology|September 20, 2015
Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomasAgustí Alentorn, Caroline Dehais, François Ducray, et al.
Trends in Cancer|November 18, 2022
Challenges in glioblastoma research: focus on the tumor microenvironmentAndreas Bikfalvi, Cristine Alves da Costa, Tony Avril, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Neuro-Oncology Advances|May 30, 2024
TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive gliomaAlberto Picca, Anna Luisa Di Stefano, Julien Savatovsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2025
Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I StudyDinu Stefan, Paul Lesueur, Justine Lequesne, et al.
Cancers|November 26, 2022
Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade <i>IDH</i>-Mutant Gliomas: A French POLA Network StudyColine Montégut, Jean-Sébastien Guillamo, François Ducray, et al.
Neuro-Oncology|August 11, 2022
Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network studyAntoine Seyve, Caroline Dehais, Olivier Chinot, et al.
Trends in Cancer|March 30, 2023
Challenges in glioblastoma research: focus on the tumor microenvironment: (Trends in Cancer, 9:1 p:9-27, 2023)Andreas Bikfalvi, Cristine Alves da Costa, Tony Avril, et al.
Neurology|September 20, 2015
Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomasAgustí Alentorn, Caroline Dehais, François Ducray, et al.
Trends in Cancer|November 18, 2022
Challenges in glioblastoma research: focus on the tumor microenvironmentAndreas Bikfalvi, Cristine Alves da Costa, Tony Avril, et al.
Pageof 3